News & Events
27 June 2018
Open Call: MRFF Clinical Trials Activity for Rare Cancers, Rare Diseases and Unmet Needs
This competitive call recently opened by the MRFF will provide support for publicly funded clinical trials that address areas of health burden and unmet need, such as rare cancers and rare diseases. Applications to this grant opportunity must propose a clinical trial that addresses an ‘unmet medical need’* by improving the health outcomes for members of the Australian community living with serious health conditions whose diagnosis or treatment is not adequately addressed by existing options.
*Definition: unmet medical need
According to the Grant Guidelines, submissions must provide "evidence to demonstrate, that the clinical trial addresses a health condition, or brain cancer, with limited effective treatment options. Where the condition is rare (i.e. affects less than 1 in 2000 of the Australian population) this should be clearly stated and substantiated by referencing a publicly available dataset or equivalent."
Minimum data due by Wednesday 1 August 2018
Applications close Wednesday 15 August 2018
MACH partner researchers intending to submit applications for this scheme and seeking advice or proposal support to address capability gaps in the areas of Indigenous health outcomes and/or consumer-community engagement are encouraged to contact MACH Project Officer Nick Walsh at firstname.lastname@example.org by 16 July with details.
This will enable us to assist researchers in addressing these gaps where possible through the MACH network.
Please also note that researchers submitting bids through the University of Melbourne are requested to submit a Notice of Intent through the University in order to trigger research office support.
NHMRC's Medical Research Future Fund (MRFF) funds cutting-edge health and medical research, directly investing into the health of Australians, the economy and the sustainability of the Australian health system. They are looking for "the next penicillin, pacemaker, cervical cancer vaccine or bionic ear."